Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07547995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 33% 111 → 74 participants
See other at-risk trials from Changchun GeneScience Pharmaceutical Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 111 → 74 participantsv2 Show 6 more changesShow less
    • Recruitment opened
    • Trial arms changed: 3 → 2
    • Start date changed from estimate of Jun 18, 2026 to Jun 29, 2026
    • Interventions: GenSci048 High-dose (Drug), GenSci048 Low-dose (Drug), Placebo (Drug) to GenSci048 (Drug), Placebo (Drug)
    • Eligibility criteria expanded, about 24 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.
Trial Details
NCT Number NCT07547995
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Uveitis
Related terms Uveitis
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov